NEW HAVEN, Conn.--CuraGen recently announced the launch of a product line based on SeqCalling, a proprietary process for rapidly generating sequence information by focusing on expressed genes and regions of the genes that code for proteins. SeqCalling locates rarely expressed genes without the problem of nonproductive resequencing of abundant genes, and without sequencing noncoding DNA, the company claimed.
Human and rodent SeqCalling databases are available with broad coverage of the expressed genomes. Current SeqCalling databases provide detailed information on specific species and tissues of interest. For example, the rat liver database contains more than 75 percent of all the genes expressed in that organ and is helpful in understanding drug toxicity.
The product line will accelerate the discovery of protein therapeutics, targets for small-molecule drugs, and gene-based single-nucleotide polymorphisms, CuraGen claimed.